News
Hosted on MSN25d
Clinical trial suggests new drug candidate for spinocerebellar ataxia may offer certain therapeutic benefitsSpinocerebellar ataxia (SCA ... a group of disorders caused by proteins with abnormal long polyglutamine (polyQ) tracts. These proteins accumulate within nerve cells, forming aggregates that ...
Steminent Biotherapeutics specializes in developing innovative stem cell-based therapeutics that offer new hope for patients ...
for spinocerebellar ataxia type 27B (SCA27B). This pivotal-powered study will be funded in part by a $7.3 million dollar grant awarded to Dr. Susan Pearlman, MD, at the University of California, Los ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results